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journal homepage: www.j fma-onl ine.comCORRESPONDENCESister Mary Joseph nodule associated with
pancreatic adenocarcinomaChi-Hsuan Chiang, Ming-Hsien Lin*Department of Dermatology, Chi Mei Medical Center, Tainan City, TaiwanReceived 22 March 2013; accepted 4 April 2013A 64-year-old man presented with a 1-month history of
painless nodule on the umbilicus (Fig. 1A). He had no his-
tory of abdominal pain, poor appetite, bowel habit change,
or body weight loss. The skin biopsy of the umbilical nodule
revealed dermal infiltration of tubuloglandular neoplastic
cells, which were stained strongly positive for cytokeratin 7
and weakly positive for cytokeratin 20. All laboratory test
results were within normal ranges, except a remarkable
elevation in the tumor marker CA19-9 level of 12000 U/mL
(normal: 37 U/mL). The abdominal computed tomography
confirmed a 3.8 cm mass at the pancreatic tail (Fig. 1B,
arrow), with pancreatic duct dilatation, multiple foci of
liver metastasis, and peritoneal carcinomatosis. Gastroin-
testinal endoscopy, chest X-ray, and whole-body bone scan
showed negative results for tumor surveillance. Under the
diagnosis of pancreatic adenocarcinoma with multiple me-
tastases, the patient was transferred to the oncology
department for chemotherapy.
Cutaneous metastases from an internal malignancy have
been reported in 0.7e10.4% of patients.1,2 Sister Mary Jo-
seph nodule (SMJN) is a cutaneous nodule resulting from
metastasis of malignant tumors affecting the umbilicus.
SMJN is commonly associated with a primary adenocarci-
noma of the gastrointestinal or genitourinary tract. Umbili-
cal involvement in an internal malignancy may result from
lymphatic or hematogenous spread, direct invasion into theFigure 1 (A) Painless umbilical nodule (1.2 cm) with serous
discharge. (B) Tumor at the pancreatic tail (arrow), with
pancreatic duct dilatation.
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Sister Mary Joseph nodule & pancreatic adenocarcinoma 93skin, or iatrogenic implantation by surgical procedures.3 We
reviewed 465 SMJN cases, which were reported by 2012
(table not shown), and found that the most common primary
site of malignancy was the stomach (20.65%), followed by
the ovary (17.85%), large intestine (12.04%), and pancreas
(9.25%). It was worth noting that the primary tumor of un-
known origin accounted for 15% of the cases.
Searching for the sites of primary malignant tumors is
essential when the diagnosis of SMJN is made. Immunohis-
tochemical markers are useful to define tumor lineage from
tissue specimens for unknown primary cancer. Monoclonal
antibodies to cytokeratin 7 and cytokeratin 20 have been
used to classify tumors because of their distinct expression
by different organs.4 The cytokeratin 7þ/20þ phenotype
narrowed the differential diagnoses to urothelial tumors,
ovarian mucinous adenocarcinoma, cholangiocarcinoma,
and pancreatic adenocarcinoma.4 Based on the results of
imaging studies and cytokeratin staining, it is clinically
rational to conclude that the primary tumor site of this
patient was the pancreas, without performing further bi-
opsy of pancreatic tail or hepatic nodules.
The presence of SMJN often means a poor prognosis. The
survival time without treatment ranged from 2 months to 11
months (average 10 months).3,5 Only 13.5% of patients withSMJN stayed alive after 2 years of umbilical metastasis, and
the longest survival time reported was 18 years.3
In summary, we delineated a case with an end-stage
pancreatic cancer with SMJN as the first presenting sign.
SMJN is a characteristic but easily overlooked dermatolog-
ical sign of metastatic intra-abdominal tumors. Awareness
of such a specific manifestation enables the physicians to
investigate the underlying malignancy promptly.References
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